Skip to main content

Post Partum Haemorrhage

0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Baymatob Operations
Baymatob OperationsAustralia - Leichhardt
1 program
OliN/A1 trial
Active Trials
NCT06655207Recruiting1,000Est. Jul 2026
Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
CarbetocinPHASE_31 trial
Active Trials
NCT02216383Completed5,798Est. Oct 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsCarbetocin
Baymatob OperationsOli

Clinical Trials (2)

Total enrollment: 6,798 patients across 2 trials

NCT02216383Ferring PharmaceuticalsCarbetocin

Intramuscular Oxytocics: A Randomised Control Trial

Start: Feb 2015Est. completion: Oct 20185,798 patients
Phase 3Completed
NCT06655207Baymatob OperationsOli

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

Start: Aug 2025Est. completion: Jul 20261,000 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 6,798 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.